Press Releases

November 13, 2019	Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care Award
November 12, 2019	Verastem Oncology Announces Private Exchange of Approximately $114.3 Million of its 5.00% Convertible Senior Notes due 2048 for 5.00% Convertible Senior Second Lien Notes Due 2048
November 6, 2019	Verastem Oncology to Present Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting
October 29, 2019	Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress
October 23, 2019	Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress
October 17, 2019	Verastem Oncology to Announce Third Quarter 2019 Financial Results and Corporate Update on October 29, 2019
October 7, 2019	Verastem Oncology Announces Dosing of First Patient in Yakult Honsha Co., Ltd.’s Japanese Bridging Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
October 4, 2019	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 3, 2019	Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma
October 3, 2019	Verastem Oncology Presents New Preclinical Duvelisib Data at the 5th International Conference on New Concepts in Lymphoid Malignancies
September 26, 2019	Verastem Oncology to Present at the Cantor 2019 Global Healthcare Conference
September 20, 2019	Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the 18th Annual International Workshop on Chronic Lymphocytic Leukemia
September 3, 2019	Verastem Oncology to Present at the 21st Annual H.C. Wainwright Global Investment Conference
September 3, 2019	Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Society of Hematologic Oncology 2019 Annual Meeting
August 1, 2019	Verastem Oncology Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
July 29, 2019	Verastem Oncology Appoints Brian Stuglik as Chief Executive Officer
July 25, 2019	Verastem Oncology Signs an Exclusive License Agreement with Sanofi for the Development and Commercialization of COPIKTRA® (duvelisib) in Russia and CIS, Turkey, the Middle East and Africa
July 25, 2019	Verastem Oncology to Announce Second Quarter 2019 Financial Results and Corporate Update on August 1, 2019
July 3, 2019	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 21, 2019	Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on Malignant Lymphoma
June 20, 2019	Verastem Oncology Announces Leadership Changes
June 17, 2019	Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting
May 30, 2019	Verastem Oncology to Present at the Jefferies 2019 Global Healthcare Conference
May 16, 2019	Verastem Oncology to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
May 15, 2019	Verastem Oncology to Present New COPIKTRA™ (Duvelisib) Dose Modification Data from Patients Treated in the Phase 3 DUO Study
May 9, 2019	Verastem Oncology Reports First Quarter 2019 Financial Results
May 2, 2019	Verastem Oncology to Announce First Quarter 2019 Financial Results and Corporate Update on May 9, 2019
April 23, 2019	Verastem Oncology Announces Amendment to Refinance Hercules Loan Facility
April 4, 2019	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 2, 2019	Verastem Oncology to Present at the H.C. Wainwright Global Life Sciences Conference
March 12, 2019	Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate Developments
March 12, 2019	Verastem Oncology to Present at Upcoming Investor Conferences
March 7, 2019	Verastem Oncology Presents Further COPIKTRA™ (Duvelisib) Data at the 23rd Annual International Congress on Hematologic Malignancies
March 4, 2019	Verastem Oncology Presents Phase 3 DUO™ Data Evaluating COPIKTRA™ (Duvelisib) in Patients with CLL/SLL Who Have Progressed Following Two Prior Lines of Therapy
March 1, 2019	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 26, 2019	Verastem Oncology to Announce Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update on March 12, 2019
February 21, 2019	Verastem Oncology to Present at the 8th Annual SVB Leerink Global Healthcare Conference
February 20, 2019	Verastem Oncology Announces Key Management Appointments
February 14, 2019	Verastem Oncology Announces Publication of the Phase 2 DYNAMO Study Results in Indolent Non-Hodgkin Lymphoma in the Journal of Clinical Oncology
February 4, 2019	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 7, 2019	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 3, 2019	Verastem Oncology Outlines Strategic Priorities for 2019 and Highlights Recent Progress
January 3, 2019	Verastem Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference

E-mail Alerts

You may automatically receive Verastem Oncology financial information by e-mail. To choose your options for e-mail notification, please enter your e-mail address below and click Submit.

Required fields denoted by an asterisk ().

Alert type
Verastem Inc End-of-Day Stock Quote Alert
Verastem Inc SEC Alert
Verastem Inc Calendar Alert
Verastem Inc News Alert

Press Releases

E-mail Alerts

Investor Contact

John Doyle

Joe Rayne